STOCK TITAN

Kura Oncology Inc - KURA STOCK NEWS

Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.

Overview of Kura Oncology Inc

Kura Oncology Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company driven by the promise of precision medicines for cancer. Operating at the forefront of the genomics revolution, the company targets cancer signaling pathways with innovative small molecule drug candidates, positioning itself at the nexus of targeted therapy and personalized oncology. With a robust focus on precision medicine, Kura Oncology integrates cutting-edge research and a deep understanding of cancer genetics to develop therapies that are safer and more effective for patients with specific genetic profiles.

Core Business and Pipeline

Kura Oncology’s pipeline reflects its commitment to addressing high unmet medical needs in oncology. The company is developing targeted therapies that interfere with key molecular interactions in cancer cells. A central focus is on ziftomenib, a once-daily, oral menin inhibitor designed to disrupt the menin-KMT2A interaction, which plays a pivotal role in the pathogenesis of acute myeloid leukemia (AML) and other hematologic malignancies. The company’s approach leverages detailed insights into cancer genetics to offer precision treatments capable of identifying and targeting patient-specific cancer profiles.

Scientific Innovation and Market Position

The scientific strategy at Kura Oncology is built on a clear understanding that a patient’s genetic makeup drives treatment response. This knowledge has informed the company’s comprehensive development programs, targeting not only hematologic cancers such as various forms of leukemia and lymphoma but also solid tumors including lung, colorectal, thyroid, and pancreatic cancers. By tailoring its therapeutic approaches based on cancer genomics, Kura Oncology aspires to craft treatments that uniquely address the vulnerabilities of cancer cells, thereby offering enhanced efficacy and minimized toxicity compared to traditional therapies.

Collaborations and Clinical Development

In recognition of the complexities of modern drug development, Kura Oncology has engaged in strategic collaborations with global partners to further its goals. These partnerships enhance its capabilities throughout the clinical and regulatory process, ensuring comprehensive development and streamlined commercialization strategies. Kura’s work on ziftomenib, for instance, has already garnered attention in clinical settings and regulatory agencies, reflecting robust safety and efficacy profiles as observed in multiple clinical studies.

Commitment to Precision Medicine

The company’s mission is not only to develop novel treatments but also to fundamentally change the way cancer is treated by integrating precision medicine into clinical practice. This involves sophisticated diagnostics and companion tests that help identify patients who are most likely to benefit from targeted treatments. Such a model is emblematic of Kura Oncology’s forward-thinking approach, wherein advanced molecular insights drive tailored therapeutic strategies that aim to significantly improve patient outcomes.

Industry Terminology and Strategic Insights

Throughout its operations, Kura Oncology employs industry-specific terminology such as "targeted therapy," "desired pharmacological profiles," and "companion diagnostics" to underscore its technical expertise. By focusing on the genetic underpinnings of cancer, the company not only differentiates itself from more conventional treatment modalities but also reinforces its market position as a specialist in precision oncology. Each element of the company’s strategy is supported by a clear scientific rationale, reflecting a mature and methodical approach to drug discovery and development.

Conclusion

Kura Oncology Inc remains dedicated to advancing the boundaries of cancer therapy with a focus on precision medicine. By combining genetic insights, groundbreaking research, and strategic global collaborations, the company delivers a deep reservoir of expertise in the biopharmaceutical arena. Investors and industry analysts recognize Kura’s distinctive model as it continues to evolve through clinical innovation and development, marking its importance in the competitive landscape of modern oncology.

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced the successful closing of its public offering, selling 9,326,500 shares at $37.00 each, yielding approximately $345.1 million gross proceeds. The underwriters fully exercised their option to purchase an additional 1,216,500 shares. The offering was conducted under a shelf registration effective December 7, 2020. SVB Leerink, Credit Suisse, Barclays, and Stifel served as joint bookrunning managers. Kura aims to utilize these funds to advance its clinical-stage pipeline targeting cancer treatments, particularly focusing on precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicine, will participate in the JMP Securities Hematology Summit on December 15, 2020. CEO Troy Wilson will take part in a fireside chat at 11:00 a.m. ET. The summit is hosted virtually from December 15-16, 2020. A live audio webcast of the discussion will be available on Kura's website, with a replay accessible for 30 days. Kura's leading drug candidate is tipifarnib, aimed at treating HRAS mutant head and neck squamous cell carcinoma, alongside KO-539 for acute myeloid leukemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) has announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at $37.00 per share, aiming for gross proceeds of approximately $300 million. The offering includes a 30-day option for underwriters to purchase an additional 1,216,500 shares. The expected closing date is December 11, 2020, pending customary conditions. The securities are offered under a previously filed shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) has initiated an underwritten public offering to sell $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions, and no assurance is given regarding its completion. The shares will be offered under a shelf registration statement filed with the SEC. The transaction will be managed by SVB Leerink, Credit Suisse, Barclays, and Stifel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
-
Rhea-AI Summary

Kura Oncology announced preliminary data from its Phase 1/2A clinical trial of KO-539, an oral menin inhibitor, for treating relapsed/refractory acute myeloid leukemia (AML). Encouraging results showed evidence of biologic activity in all dose-escalation cohorts, with two complete remissions (CR) in patients with specific genetic mutations. The continuous dosing of KO-539 was well tolerated with manageable safety, and Kura plans to recommend a Phase 2 dose and advance to expansion cohorts in early 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Kura Oncology will host a virtual investor event on December 5, 2020, at 2:00 p.m. ET to discuss preliminary clinical data regarding its menin inhibitor, KO-539, following its presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature Kura's management team and investigators from the ongoing KOMET-001 trial. A live video webcast will be available on Kura's website, with an archived replay accessible after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
Rhea-AI Summary

Kura Oncology reported third quarter 2020 results, highlighting significant developments in its clinical pipeline and financial standing. Preliminary data from the KOMET-001 trial of KO-539, a menin inhibitor, showed promising safety and anti-leukemic activity. The drug is nearing a recommended Phase 2 dose with expansion cohorts planned for specific AML populations. Additionally, preclinical data supports the combination of tipifarnib with a PI3Kα inhibitor for treating HRAS-dependent HNSCC. Kura ended Q3 2020 with $325.4 million in cash, ensuring operational support into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
-
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced participation in three upcoming virtual investor conferences. CEO Troy Wilson will present at the Credit Suisse 29th Annual Healthcare Conference on November 11, 2020, at 10:15 a.m. ET. CFO Marc Grasso will speak at the Stifel Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat with Dr. Wilson will be available on Kura's website during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. Live audio webcasts will also be accessible on Kura's IR website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology (KURA) will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call and webcast will follow at 8 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing precision cancer treatments, with its lead candidate, tipifarnib, in a registration-directed trial for HRAS mutant head and neck cancer. Kura also has KO-539, a menin inhibitor in Phase 1/2A trials for acute myeloid leukemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences earnings
Rhea-AI Summary

Kura Oncology has unveiled new preclinical data supporting the use of tipifarnib in treating HRAS/PI3K-dependent tumors, which account for up to 50% of head and neck squamous cell carcinoma (HNSCC) cases. The company plans to initiate a Phase 1/2 proof-of-concept study combining tipifarnib with a PI3Kα inhibitor in relapsed/refractory HNSCC. Current estimates suggest that 20% of HNSCC patients overexpress HRAS while 35% have PIK3CA mutations. Kura's ongoing AIM-HN trial focuses on HRAS mutant HNSCC, which affects 4-8% of patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags

FAQ

What is the current stock price of Kura Oncology (KURA)?

The current stock price of Kura Oncology (KURA) is $5.89 as of April 4, 2025.

What is the market cap of Kura Oncology (KURA)?

The market cap of Kura Oncology (KURA) is approximately 478.9M.

What is Kura Oncology's primary focus?

Kura Oncology is dedicated to advancing precision medicines for cancer by developing targeted small molecule drugs that address specific genetic profiles in tumors.

Which cancers does Kura Oncology target?

The company focuses on cancers with high unmet needs, including acute myeloid leukemia, as well as various solid tumors such as lung, colorectal, thyroid, and pancreatic cancers.

What is the role of ziftomenib in Kura Oncology's pipeline?

Ziftomenib is a selective, oral menin inhibitor developed to disrupt key protein interactions in cancer cells, particularly targeting mutations in acute myeloid leukemia.

How does Kura Oncology utilize precision medicine?

The company leverages advancements in genomics and companion diagnostics to tailor treatments to the unique genetic makeup of each patient’s cancer, optimizing safety and efficacy.

What types of drug candidates does Kura Oncology develop?

Kura Oncology develops small molecule drug candidates that interfere with cancer signaling pathways, aiming to provide transformative treatment options with improved patient outcomes.

How does Kura Oncology maintain its competitive edge?

Through innovative approaches grounded in cutting-edge research, strategic collaborations, and a focus on precision medicine, Kura Oncology distinguishes itself by targeting genetic vulnerabilities in cancer.

What phase are Kura Oncology's clinical trials in?

As a clinical-stage company, Kura Oncology conducts multiple trials evaluating the safety and efficacy of its drug candidates in patient populations with specific cancer types.

Does Kura Oncology collaborate with other organizations?

Yes, the company has strategic partnerships with global pharmaceutical entities to enhance developmental, regulatory, and commercial capabilities for its therapies.
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

KURA Stock Data

478.88M
77.98M
1.15%
102.19%
11.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO